Tadalafil Therapy for Pulmonary Arterial Hypertension

@article{Gali2009TadalafilTF,
  title={Tadalafil Therapy for Pulmonary Arterial Hypertension},
  author={Nazzareno Gali{\`e} and Bruce H. Brundage and Hossein Ardeschir Ghofrani and Ronald J. Oudiz and G{\'e}rald Simonneau and Zeenat Safdar and Shelley M. Shapiro and R. James White and Melanie Chan and Anthony Beardsworth and Lyn Robert Frumkin and Robyn J. Barst},
  journal={Circulation},
  year={2009},
  volume={119},
  pages={2894-2903}
}
Background— Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway. Methods and Results— In this 16-week, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or associated), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan… Expand
Tadalafil: in pulmonary arterial hypertension.
TLDR
Preliminary data from an extension of the PHIRST trial suggest that the improvements in 6MWD are maintained for up to 1 year in recipients of tadalafil 20 or 40 mg once daily. Expand
Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
TLDR
This study enhanced understanding of oral treprostinil titration and dosing, which has set the stage for additional studies. Expand
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
TLDR
The risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo and there was no significant difference in mortality between the two study groups. Expand
Tadalafil for the treatment of pulmonary arterial hypertension
  • J. Klinger
  • Medicine
  • Expert review of respiratory medicine
  • 2011
TLDR
The role of cGMP and PDE-5 in PAH is reviewed, the results of recent clinical trials are presented and the role of tadalafil in the treatment of this rare but difficult-to-treat disease is discussed. Expand
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial HypertensionClinical Perspective
TLDR
Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common, and further studies are needed to investigate the long-term safety and efficacy of imatinib in Patients with PAH. Expand
Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study.
TLDR
Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily and was associated with only mild and transient adverse events. Expand
Riociguat for the treatment of pulmonary arterial hypertension.
TLDR
Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension and showed significant improvements in pulmonary vascular resistance, NT-proBNP levels, World Health Organization functional class, and time to clinical worsening. Expand
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study
TLDR
The findings support dual PDE5i therapy as a new treatment option for refractory PAH and generally well tolerated without severe adverse events. Expand
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study
TLDR
Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common, and further studies are needed to investigate the long-term safety and efficacy of imatinib in Patients with PAH. Expand
Tadalafil for the treatment of pulmonary arterial hypertension
TLDR
Clinical properties such as its long half-life leading to once-daily dosing and possibly improved compliance, as well as potential cost benefit, may distinguish tadalafil from sildenafil in the widespread treatment of PAH. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Sildenafil citrate therapy for pulmonary arterial hypertension.
TLDR
Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo. Expand
BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION
A BSTRACT Background Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exerciseExpand
Ambrisentan therapy for pulmonary arterial hypertension.
TLDR
Ambrisentan appears to improve exercise capacity, symptoms, and hemodynamics in patients with PAH, and the incidence and severity of liver enzyme abnormalities appear to be low. Expand
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
TLDR
Treatment with the selective ET(A) receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity. Expand
Sitaxsentan therapy for pulmonary arterial hypertension.
TLDR
Although the 300-mg group increased peak VO(2) compared with placebo (+3.1%, p < 0.01), none of the other endpoints derived from cardiopulmonary exercise testing were met and neither the functional class, cardiac index, and pulmonary vascular resistance improved. Expand
Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide
TLDR
A single oral dose of sildenafil is as effective and selective a pulmonary vasodilator as iNO and may be superior to iNO in that it increases cardiac output and does not increase wedge pressure. Expand
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
TLDR
Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension, suggesting that endothelin has an important role in pulmonary hypertension. Expand
Inhaled iloprost for severe pulmonary hypertension.
TLDR
Inhaled Iloprost is an effective therapy for patients with severe pulmonary hypertension and hemodynamic values were significantly improved at 12 weeks when measured after iloprost inhalation, and were significantly worse in the placebo group. Expand
Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension.
TLDR
Sildenafil improves HRQoL of PAH patients and the effects are strongest in domains addressing the physical impact of health on daily activities and patients' overall perception of health. Expand
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
TLDR
Results of this study demonstrate that the addition of inhaled iloprost in patients with PAH with reduced exercise capacity on bosentan monotherapy is safe and efficacious. Expand
...
1
2
3
4
5
...